Get started
ABBOTT LABORATORIESABBOTT LABORATORIESABBOTT LABORATORIES

ABBOTT LABORATORIES

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

ABT trade ideas

ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here: or sold it here: Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 91usd strike price Calls with an expiration date of 2023-10-27, for a premium of approximately $3.15. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:ABTLong
by TopgOptions
2
Abott to turnaround at trend line support?Abbott Laboratories - 30d expiry - We look to Buy at 104.11 (stop at 100.91) The trend of higher lows is located at 104. The primary trend remains bullish. This stock has seen good sales growth. 104 continues to hold back the bears. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible. Our profit targets will be 112.11 and 114.11 Resistance: 106.20 / 108.50 / 110.00 Support: 103.28 / 100.38 / 99.30 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group
NYSE:ABTLong
by VantageMarkets
ABT - 9 months SYMMETRICAL TRIANGLE══════════════════════════════ Since 2014, my markets approach is to spot trading opportunities based solely on the development of CLASSICAL CHART PATTERNS 🤝Let’s learn and grow together 🤝 ══════════════════════════════ Hello Traders ✌ After a careful consideration I came to the conclusion that: - it is crucial to be quick in alerting you with all the opportunities I spot and often I don't post a good pattern because I don't have the opportunity to write down a proper didactical comment; - since my parameters to identify a Classical Pattern and its scenario are very well defined, many of my comments were and would be redundant; - the information that I think is important is very simple and can easily be understood just by looking at charts; For these reasons and hoping to give you a better help, I decided to write comments only when something very specific or interesting shows up, otherwise all the information is shown on the chart. Thank you all for your support 🔎🔎🔎 ALWAYS REMEMBER "A pattern IS NOT a Pattern until the breakout is completed. Before that moment it is just a bunch of colorful candlesticks on a chart of your watchlist" ═════════════════════════════ ⚠ DISCLAIMER ⚠ The content is The Art Of Charting's personal opinion and it is posted purely for educational purpose and therefore it must not be taken as a direct or indirect investing recommendations or advices. Any action taken upon these information is at your own risk.
NYSE:ABTLong
by TheArtOfCharting
Abbott triggered by positive earnings Abbott Laboratories Second-Quarter Results Beat Expectations Despite Lower COVID-19 Testing Sales The company now anticipates about $1.3 billion in sales from COVID-19 testing products for 2023, compared with the prior forecast of $1.5 billion, "due to current testing dynamics, including lower demand for testing following the end of the public health emergency in May," Chief Financial Officer Robert Funck said on the call. For the third quarter, Abbott anticipates adjusted earnings of roughly $1.10 per share, according to Funck. Analysts estimate EPS of $1.11. Technicals: Cycle Sniper Reversal Filter Headed Nort Cycle Sniper Bullish ddeviation Key Resistance: 116 $ Closing above 116 $ Targets: 122 $ and 128 $
NYSE:ABTLong
by chartreader_pro
Abbott Laboratories in a bull flag.Abbott Labratories - 30d expiry - We look to Buy a break of 109.51 (stop at 106.31) The primary trend remains bullish. This stock has seen good sales growth. Expect trading to remain mixed and volatile. 109.34 has been pivotal. Posted a bullish Flag formation. A break of 109.34 is needed to confirm the outlook. The bias is to break to the upside. Our profit targets will be 117.51 and 119.51 Resistance: 108.50 / 109.34 / 112.95 Support: 106.80 / 105.96 / 104.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group.
NYSE:ABTLong
by VantageMarkets
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here: Then analyzing the options chain of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 108usd strike price in the money Puts with an expiration date of 7/21/2023, for a premium of approximately $2.55. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:ABTShort
by TopgOptions
ABT a slow moving low beta medical stockABT is Abbott Labs, a well-established medical technology company has had good earnings twice this year. In the first episode, the price trended down then recovered in a retracement. I have anchored a long-term mean VWAP and its standard deviations as a means to assess areas of dynamic support and resistance. One week ago, the price crossed the mean VWAP in its uptrend. I see this as a good place for a long trade over a month or more. For a stop loss I will place the stop below the mean VWAP also confluent with two horizontal support lines as well as the rising support trendline and the POC line of the volume profile Targets are the first and second standard deviations at about $105 and $110. I will make an optimal entry from a pivot low on a timeframe of 30-90 minutes. As the anticipated ROI is relatively small although with reasonable risk, my approach is a call option for mid-September with a strike in the range of $100-104. I expect this to yield 25% or more monthly until signs of a pullback or reversal. While the general market has heightened volatility and controlled chaos, I see adding some trades of slow-moving low beta stocks to be proper risk management.
NYSE:ABTLong
by AwesomeAvani
ABT Abbott Labs Med Tech Short Setting UpABT is shown on a 4H chart as setting up for a short trade. Demand and Summply Zones are charted by the LuxAlgo indicator. Price touched the supply zone five times in December- January then descended and touched the demand zone several times in mid-March. Fundamentally, earnings reports have been solid. Medical stocks are generally independent of the economy and recession resilient. ABT has risen off the base of bottoms at support . Relative volume exceeds that of the past year showing investor/trader interest has increased. I think it will progress to touch the supply / resistance zone another once or twice and then reverse into a solid downtrend. I see this as worth watching this upcoming week for the reversal.
NYSE:ABTShort
by AwesomeAvani
ABT = bull pennantABT had exhibited great momentum for the past few weeks with the recent earnings on 19 Apr propelling it to gap up on high volume. It appears to be forming a bull pennant right now. It is possible to trade the breakup of this pennant (initial stop just below the gap up candle), however bear in mind that the overhead resistance at 114 - 116 might be difficult to overcome in the near term. Short term trade for time being. Let's see. Disclaimer: Just my 2 cents and not a trade advice. Kindly do your own due diligence and trade according to your own risk tolerance and don't forget that money management is important! "Let winners run and cut losses short". Take care and Good Luck!
NYSE:ABT
by Juliac
Risky Move on Abbott. ABTA collection of confluent clues. 0.786 retrace on A, quadruple pincers, low volume, RSX OBOS probably peaking, P/C ratio momentally toward green. Swing low within significant count of swing high (? Fib 1:1 ratio timewise). If it doesn't swing, stop loss is close and will not break this bank. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:ABTLong
by Rykin_Capital